Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 1 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 2

Study Type

Interventional 6

Sponsor

Conditions

Leiomyoma 6Myofibroma 1Metrorrhagia 1Menorrhagia 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
ulipristal × Clear all
NCT00290251 2024-07-15

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
72 enrolled 7 charts

Leiomyoma

NCT04832906 2021-04-06

UA Versus UAE in Treatment of Fibroids

Ain Shams Maternity Hospital

Phase 4 Completed
70 enrolled

Leiomyoma, Metrorrhagia

NCT03342859 2021-01-06

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Bayer

Phase 1 Terminated
10 enrolled

Leiomyoma

NCT00044876 2019-12-17

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
56 enrolled

Leiomyoma, Myofibroma

NCT02465814 2016-11-22

ASTEROID 2

Bayer

Phase 2 Completed
120 enrolled

Leiomyoma, Menorrhagia

NCT02288130 2016-11-03

MYOMEX

Amsterdam UMC, location VUmc

Phase 4 Unknown
100 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡